JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on AstraZeneca (LON:AZN) in a research report report published on Tuesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently commented on the stock. Kepler Capital Markets set a GBX 6,470 ($84.54) target price on shares of AstraZeneca and gave the stock a buy rating in a research note on Monday, May 13th. Citigroup reissued a buy rating and set a GBX 7,000 ($91.47) target price on shares of AstraZeneca in a research note on Monday, May 13th. Morgan Stanley boosted their target price on shares of AstraZeneca from GBX 6,400 ($83.63) to GBX 6,500 ($84.93) and gave the stock an equal weight rating in a research note on Tuesday, May 7th. UBS Group reissued a sell rating and set a GBX 5,400 ($70.56) target price on shares of AstraZeneca in a research note on Thursday, July 25th. Finally, Goldman Sachs Group set a GBX 5,000 ($65.33) target price on shares of AstraZeneca and gave the stock a sell rating in a research note on Thursday, July 25th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the stock. The company has an average rating of Hold and an average target price of GBX 6,629.41 ($86.63).
AZN stock opened at GBX 7,240 ($94.60) on Tuesday. The stock has a market capitalization of $94.97 billion and a PE ratio of 42.29. The stock’s 50-day moving average is GBX 6,523.88. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 130.83. AstraZeneca has a 52 week low of GBX 5,312 ($69.41) and a 52 week high of GBX 7,349.30 ($96.03).
In other AstraZeneca news, insider Marc Dunoyer acquired 8,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was bought at an average price of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Correction
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.